The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | BTK inhibitors and their place in the treatment landscape of B-cell malignancies
Katharine L. Lewis, BMBS, FRCPath, MRCPath, Sir Charles Gairdner Hospital, Nedlands, Australia, shares her insights into advancements in treatment options for patients with B-cell malignancies, drawing focus on Bruton’s tyrosine kinase (BTK) inhibitors. First, Dr Lewis discusses some of the BTK inhibitors that have been developed, including ibrutinib, acalabrutinib and zanubrutinib, and their role in treatment. Following this, Dr Lewis draws focus on non-covalent BTK inhibitors, namely pirtobrutinib, and the promising data that has been presented on the effectiveness of this BTK inhibitor in treating B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
